作者
Itamar Raz, Ofri Mosenzon, Marc P Bonaca, Avivit Cahn, Eri T Kato, Michael G Silverman, Deepak L Bhatt, Lawrence A Leiter, Darren K McGuire, John PH Wilding, Ingrid AM Gause‐Nilsson, Anna M Langkilde, Peter A Johansson, Marc S Sabatine, Stephen D Wiviott
发表日期
2018/5
期刊
Diabetes, Obesity and Metabolism
卷号
20
期号
5
页码范围
1102-1110
出版商
Blackwell Publishing Ltd
简介
Aim
To describe the baseline characteristics of participants randomized in the Dapagliflozin Effect on CardiovascuLAR Events (DECLARE‐TIMI 58) trial, the pivotal study conducted to assess cardiovascular (CV) outcomes with dapagliflozin.
Methods
The DECLARE‐TIMI 58 trial will analyse 17 160 patients with type 2 diabetes randomized to treatment with dapagliflozin (10 mg/d) or matching placebo. We analysed their baseline characteristics.
Results
The participants’ mean ± SD age was 63.8 ± 6.8 years, 62.6% were male, and their mean ± SD diabetes duration was 11.8 ± 7.8 years, glycated haemoglobin 8.3% ± 1.2% (67 mmol/mol ± 9.7 mmol/mol) and body mass index 32.1 ± 6.0 kg/m2. Randomization included 6971 (40.6%) patients with atherosclerotic CV disease (CVD), and 10 189 (59.4%) patients with multiple risk factors (MRF) for CVD (defined as men age ≥ 55 years or women ≥60 years, with at least …
学术搜索中的文章
I Raz, O Mosenzon, MP Bonaca, A Cahn, ET Kato… - Diabetes, Obesity and Metabolism, 2018